Moolec Science (MLEC) Total Non-Current Liabilities (2022 - 2026)
Moolec Science's (MLEC) quarterly Total Non-Current Liabilities came in at $93.1 million in Q1 2026, up 253.61% quarter-over-quarter from $26.3 million in Q4 2025.
Moolec Science (MLEC) Total Non-Current Liabilities (2022 - 2026) Analysis & Trends
Moolec Science has disclosed Total Non-Current Liabilities across 5 years of filings, most recently posting $93.1 million for Q1 2026.
- Total Non-Current Liabilities for Q1 2026 came in at $93.1 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $93.1 million (changed N/A YoY), and the FY2025 annual result was $53.1 million, down 80.53% from the prior year.
- Total Non-Current Liabilities came in at $93.1 million for Q1 2026 at Moolec Science, up from $26.3 million in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $272.4 million in Q2 2024 to a low of -$621727.0 in Q3 2022.
- The 5-year median for Total Non-Current Liabilities is $11.5 million (2024), against an average of $38.4 million.
- Across the five-year window, Total Non-Current Liabilities jumped 94884.01% in 2023 and sank 80.53% in 2025, its largest moves.
- Moolec Science's Total Non-Current Liabilities stood at $10.4 million in 2022, then sank by 39.13% to $6.4 million in 2023, then soared by 248.16% to $22.1 million in 2024, then climbed by 18.99% to $26.3 million in 2025, then surged by 253.61% to $93.1 million in 2026.
- The last three Total Non-Current Liabilities figures came in at $93.1 million (Q1 2026), $26.3 million (Q4 2025), and $53.1 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - | 42,980.09 |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - | - |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - | 11.03 Mn |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn | 95.20 Mn |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - | - |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - | - |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - | 644,700.00 |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn | 5.87 Bn |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - | 64.76 Mn |
| 10 | Moolec Science | 6.98 Bn | 6.98 Bn | - | 93.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 93.10 Mn |
| Dec 31, 2025 | 26.33 Mn |
| Jun 30, 2025 | 53.05 Mn |
| Dec 31, 2024 | 22.13 Mn |
| Sep 30, 2024 | 19.50 Mn |
| Jun 30, 2024 | 272.43 Mn |
| Mar 31, 2024 | 11.49 Mn |
| Dec 31, 2023 | 6.36 Mn |
| Sep 30, 2023 | 1.09 Mn |
| Jun 30, 2023 | 55.63 Mn |
| Mar 31, 2023 | 1.59 Mn |
| Dec 31, 2022 | 10.44 Mn |
| Sep 30, 2022 | -621,727.00 |
| Jun 30, 2022 | 4.09 Mn |
| Mar 31, 2022 | -1,682.00 |